Table 2 A gender-based comparison of descriptive study characteristics
Characteristic | Females | Males | ||||
|---|---|---|---|---|---|---|
Controls | Cases | Total | Controls | Cases | Total | |
n (col %) | n (col %) | n (col %) | n (col %) | n (col %) | n (col %) | |
Type of Second-line drug | ||||||
Alluvia | 143(94.7) | 25(89.3) | 168(93.9) | 98(94.2) | 46(80.7) | 144(89.4) |
Atazanavir | 5(3.3) | 3(10.7) | 8(4.5) | 3(2.9) | 1(1.8) | 4(2.5) |
Other PIµ | 3(2.0) | 0(0) | 3(1.7) | 3(2.9) | 10(17.5) | 13(8.1) |
Total | 151(100) | 28(100) | 179(100) | 104(100) | 57(100) | 161(100) |
TB treatment ψ | ||||||
No | 146(97.3) | 23(82.1) | 169(94.9) | 100(97.1) | 48(84.2) | 148(92.5) |
Yes | 4(2.7) | 5(17.9) | 9(5.1) | 3(2.9) | 9(15.8) | 12(7.5) |
Total | 150(100) | 28(100) | 178(100) | 103(100) | 57(100) | 160(100) |
Year of ART initiation | ||||||
Before 2001 | 6(4.0) | 2(7.1) | 8(4.5) | 1(1.0) | 21(36.8) | 22(13.7) |
2001–2005 | 91(60.3) | 15(53.6) | 106(59.2) | 79(76.0) | 26(45.6) | 105(65.2) |
2006–2010 | 44(29.1) | 9(32.1) | 53(29.6) | 20(19.2) | 10(17.5) | 30(18.6) |
2011–2015 | 10(6.6) | 2(7.1) | 12(6.7) | 4(3.8) | 0 (0) | 4(2.5) |
Total | 150(100) | 28(100) | 179(100) | 104(100) | 57(100) | 161(100) |
Type of First-line drug | ||||||
NNRTI based | 129(85.4) | 22(78.6) | 151(84.4) | 88(84.6) | 44(77.2) | 132(82.0) |
NON-NNRTI∞ | 22(14.6) | 6(21.4) | 28(15.6) | 16(15.4) | 13(22.8) | 29(18.0) |
Total | 151(100) | 28(100) | 179(100) | 104(100) | 57(100) | 161(100) |
Other comorbidities§ | ||||||
No | 139(93.3) | 28(100) | 167(94.4) | 87(83.7) | 48(84.2) | 135(83.9) |
Yes | 10(6.7) | 0(0) | 10(5.6) | 17(16.3) | 9(15.8) | 26(16.1) |
Total | 149(100) | 28(100) | 177(100) | 104(100) | 57(100) | 161(100) |
No | 139(93.3) | 28(100) | 167(94.4) | 87(83.7) | 48(84.2) | 135(83.9) |
Yes | 10(6.7) | 0(0) | 10(5.6) | 17(16.3) | 9(15.8) | 26(16.1) |
Total | 149(100) | 28(100) | 177(100) | 104(100) | 57(100) | 161(100) |
Age at the start of 2nd line ART: median (IQR) | 36 (31–41) | 35.5(31.5–38) | 36(31–41) | 43(35–49) | 39(31–48) | 42(33–49) |
CD4 at the start of 2nd line ART: median (IQR) | 155(77–253) | 65.5(15–135) | 137(62–243) | 101.5(37–230) | 78.5(28.5–205) | 93(34–205) |
VL at start of 2nd line ART: median (IQR)¥ | 37,706(12,880–135,248) | 233,700(51,014–547,922) | 50,305.5(1453.5–162,197) | 54,588(14,444–135,859) | 139,901(72,510–645,978) | 76,115(21,919.5–250,702) |
Duration on 1st line: median (IQR) | 4(2–5) | 3(1.5–4) | 3(2–5) | 3(2–5) | 4(2–6) | 3(2–6) |